| HOME | | | ABOUT ENLYTON | | | OUR TECHNOLOGY | | | PARTNERING OPPORTUNITIES | | | PRESS ROOM | | | CONTACT US |
| ||||||||||||||||||||||||||
| "Enlyton is improving cancer patient care through superior imaging, detection and therapy" | ||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||
About Enlyton
Company Profile
Current methods of imaging are limited in terms of the information provided to oncologists and surgeons. Enlyton has secured rights to technology that promises to improve the detection capabilities of diagnostic imaging, enable real-time intraoperative detection of tumor and occult neoplastic tissue, and provide a tumor antigen-specific vehicle for localized drug delivery. The company is developing a series of proprietary targeting agents for use in cancer imaging and detection.
A Collaborative R&D Partnership
Faculty members from The Ohio State University (OSU) Colleges of Medicine, Pharmacy and Engineering are among Enlyton’s founders. An associated understanding with OSU’s Office of Technology Transfer has enabled Enlyton to forge a unique relationship with OSU, the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, where portions of Enlyton’s pre-clinical laboratory experimentation and early stage clinical trial activity will be performed.
Business Strategy
Enlyton draws from resource skills of its clinicians and scientists in the discovery, in-licensing and development of novel imaging and detection tools for diagnostic and prognostic applications in the treatment of cancer. At various pre-clinical and clinical testing stages, we will pursue partnering and licensing opportunities for commercialization.